University of Louisville homepage
All experts
All experts

Brian Dong

Assoc Professor Term

School of Medicine

Orcid identifier0009-0005-5821-5172
  • Assoc Professor Term
    School of Medicine
  • UofL Health Brown Cancer Center, Hematology/Oncology, 529 S jackson St, Louisville, Kentucky, 40202, United states

SPONSORED PROJECTS

  • Genetic predisposition for malignancy
  • Neoadjuvant and adjuvant treatments for breast cancer
  • Metastatic breast cancer
  • Quality improvement in the cancer center

SPONSORED PROJECTS

  • Showing page 1 out of 2
Showing page 1, sponsored projects 1 to 25 of 33
GRANT
AWD-00000325 | WO4565: A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Inavolisib Plus a CDK4/6 Inhibitor and Letrozole versus Placebo Plus a CDK4/6 Inhibitor and Letrozole in Patients with Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
Genentech Inc_GI2 Nov 2026 - 31 Dec 2036
MORELEARN MORE
GRANT
AWD-00000392 | STML-ELA-0422: Elacestrant versus Standard Endocrine Therapy in Women and Men with Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast Cancer with High Risk of Recurrence - A Global, Multicenter, Randomized, Open-label Phase 3 Study (ELEGANT)
Parexel International, LLC5 Jul 2026 - 31 Dec 2031
MORELEARN MORE
GRANT
BNT327-05: A Phase III, multisite, randomized, double-blind trial of BNT327 in combination with chemotherapy versus placebo with chemotherapy in patients with previously untreated locally recurrent inoperable or metastatic TNBC determined ineligible for PD(L)1 therapy based on PD-L1 negative disease
ICON Clinical Research_ICON5 Jan 2026 - 31 Dec 2031
MORELEARN MORE
GRANT
AWD-00000260 | C4551002: AN INTERVENTIONAL, OPEN-LABEL, RANDOMIZED, MULTICENTER, PHASE 3 STUDY OF PF-07248144 PLUS FULVESTRANT COMPARED TO INVESTIGATOR’S CHOICE OF THERAPY IN ADULT PARTICIPANTS WITH HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE ADVANCED/METASTATIC BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR CDK4/6 INHIBITOR-BASED THERAPY
Pfizer Inc_PFIZER1 Jan 2026 - 31 Dec 2031
MORELEARN MORE
GRANT
AWD-00000242 | EA8231: A Phase III Randomized Trial of Pembrolizumab in Combination with Sacituzumab Govitecan vs Standard of Care in Anti-PD(L)1-Resistant Advanced Urothelial Cancer
ECOG ACRIN Cancer Research Group_ECOG11 Nov 2025
MORELEARN MORE
GRANT
250284|A Phase 3, R, OL St of PF-06821497 (Mevrometostat) in Combination with Enzalutamide Compared with Enzalutamide or Docetaxel in Participants with Metastatic Castration Resistant Prostate Cancer Previously Treated with Abiraterone Acetate (MEVPRO-1)
Syneos Health_SH3 Apr 2025
MORELEARN MORE
GRANT
AWD-00000214 | LoTam: A Randomized, Phase III Clinical Trial of Low-Dose Tamoxifen for Selected patients with Molecular Low-Risk Early-Stage Breast Cancer
NRG Oncology Foundation Inc_NRGOF12 Mar 2025 - 31 Dec 2030
MORELEARN MORE
GRANT
240551|A Phase Ib/III, Ol, R Study of Capivasertib plus CDK4/6 Inhibitors and Fulvestrant versus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced, Unresectable
AstraZeneca_ASTRA1 Jan 2025
MORELEARN MORE
GRANT
AWD-00000239 | A012303: ShortStop-HER2: Shortened duration of adjuvant therapy in patients with early-stage HER2+ breast cancer who achieve pCR after neoadjuvant chemotherapy with HER2 blockade
Alliance Foundation Trials LLC_AFT1 Jan 2025
MORELEARN MORE
GRANT
Short Term Intensified Pembrolizumab (Keytruda) And Tivozanib for High-Risk Renal Cell Carcinoma – Strike (A032201)
1 Jan 2025
MORELEARN MORE
GRANT
241104|NRG-BR008 - A Phase III Randomized Trial of Radiotherapy Optimization for Low-risk HER2- Positive Breast Cancer (HERO)
NRG Oncology Foundation Inc_NRGOF6 Dec 2024
MORELEARN MORE
GRANT
241001|D7630C00001 - A Phase III, Open-label, Random Study of Datopotamab Deruxtecan (Dato-DXd) in Comb With Durvalumab Compared with Investigator's Choice of Chemotherapy (Paclitaxel, Nab-paclitaxel or Gemcitabine + Carboplatin) in Comb With Pembrolizumab
AstraZeneca LP_ASTRALP11 Jun 2024
MORELEARN MORE
GRANT
240863|EA7211: A Randomized Phase III Study of Neoadjuvant Chemotherapy followed by Surgery versus Surgery Alone for Patients with High Risk RetroPeritoneal Sarcoma (STRASS 2)
ECOG ACRIN Cancer Research Group_ECOG8 Jun 2024
MORELEARN MORE
GRANT
AWD-00000236 | S2312: A Phase III Study of Cabazitaxel with or without Carboplatin in Patients with Metastatic Castrate-Resistant Prostate Cancer (MCRPC), Stratified by Aggressive Variant Signature
Southwest Oncology Group_SWOG9 Mar 2024 - 31 Dec 2035
MORELEARN MORE
GRANT
240382|D9260C00001 -A Phase III, Open-label, Randomised Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus
AstraZeneca_ASTRA7 Mar 2024
MORELEARN MORE
GRANT
240266|NRG-GU009 - Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk with Radiation (PREDICT-RT*)
NRG Oncology Foundation Inc_NRGOF1 Feb 2024
MORELEARN MORE
GRANT
240681|AZD9833 - CAMBRIA -1 - Ph III, OL, R Study to Assess the Eff and Sfety of Extended Therapy w Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients
Fortrea_FORTREA (SPN-001967)10 Jan 2024 - 31 Dec 2036
MORELEARN MORE
GRANT
250119|A Randomized Phase II Trial of Doxorubicin + Pembrolizumab Versus Doxorubicin Alone for the Treatment of Undifferentiated Pleomorphic Sarcoma (UPS) and Related Poorly Differentiated Sarcomas
ECOG ACRIN Cancer Research Group_ECOG10 Jan 2024
MORELEARN MORE
GRANT
250181|A011801 - The COMPASSHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): COMPASSHER2 Residual Disease (RD), A Double-Blinded,Phase III Randomized Trial of T-DM1 and Placebo Compared ...
Alliance for Clinical Trials in Onc_ACTO10 Jan 2024
MORELEARN MORE
GRANT
240200|W043919 - A Ph III, MC, R, OL Study Evaluating The Efficacy And Safety Of Inavolisib Plus Fulvestrant Versus Alpelisib Plus Fulvestrant In Patients ...CDK4/6 Inhibitor And Endocrine Combination Therapy
Syneos Health_SH1 Jan 2024
MORELEARN MORE
GRANT
240590|BT8009-230 -A Randomized Open-Label Phase 2/3 Study of BT8009 Monotherapy or in Combination in Participants with Locally Advanced or Metastatic Urothelial Cancer (DURAVELO-2)
Medpace Inc_MPI1 Jan 2024
MORELEARN MORE
GRANT
241045|A012103 - OPTIMICE-PCR: De-Escalation Of Therapy In Early-Stage TNBC Patients Who Achieve PCR After Neoadjuvant Chemotherapy With Checkpoint Inhibitor Therapy
Alliance for Clinical Trials in Onc_ACTO1 Jan 2024
MORELEARN MORE
GRANT
241091|BR009 - A Ph III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Pts with pN0-1, ER Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score 25 (OFSET)
NRG Oncology Foundation Inc_NRGOF1 Jan 2024
MORELEARN MORE
GRANT
250233|EA1211 - Interim FDG-PET/CT for PreDIcting REsponse of HER2+ Breast Cancer to Neoadjuvant Therapy: DIRECT trial
ECOG ACRIN Cancer Research Group_ECOG1 Jan 2024
MORELEARN MORE
GRANT
230892|FF10832-PEM-201 -A Phase 2a Study with Safety Run-in to Evaluate the Safety, Tolerability, and Preliminary Efficacy of FF-10832 Monotherapy or in Combination with Pembrolizumab in Patients with Advanced Solid Tumor
TD2 Precision Oncology_TD2PO2 Jan 2023
MORELEARN MORE